Active Filter(s):
Details:
CWP291 is a Wnt/beta-catenin inhibitor that is under development as a first-in-class treatment for acute myeloid leukemia, multiple myeloma and stomach cancer.
Lead Product(s): CWP291
Therapeutic Area: Infections and Infectious Diseases Product Name: CWP291
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020